| Literature DB >> 26066494 |
Gloria Puerto1, Lina Erazo1, Maira Wintaco1, Claudia Castro1, Wellman Ribón1, Martha Inírida Guerrero1.
Abstract
INTRODUCTION: Tuberculosis (TB) remains a primary public health problem worldwide. The number of multidrug-resistant tuberculosis (MDR TB) cases has increased in recent years in Colombia. Knowledge of M. tuberculosis genotypes defined by spoligotyping can help determine the circulation of genotypes that must be controlled to prevent the spread of TB.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26066494 PMCID: PMC4465906 DOI: 10.1371/journal.pone.0124308
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distribution of patterns of susceptibility to first-line drugs.
| Resistance Pattern | N | % |
|---|---|---|
| H+R+S+E | 66 | 8.91 |
| H+R+S | 59 | 7.96 |
| H+R+E | 5 | 0.67 |
| H+R | 17 | 2.29 |
| H+S+E | 12 | 1.62 |
| H+S | 90 | 12.15 |
| H+E | 4 | 0.54 |
| R+E | 1 | 0.13 |
| S+E | 1 | 0.13 |
| S+R | 1 | 0.13 |
| E | 8 | 1.08 |
| H | 78 | 10.53 |
| R | 3 | 0.4 |
| S | 115 | 15.52 |
| Sensitive | 246 | 33.2 |
| No data | 35 | 4.72 |
| TOTAL | 741 | 100 |
H: Isoniazid, R: Rifampicin; S: Streptomycin: E: Ethambutol.
Distribution of the identified genotypes by family and frequency among the drug-susceptible phenotypes.
| FAMILY | SIT | Total | Resistant | Sensitive | No data | |||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | ||
| Beijing | 190 | 23 | 3.1 | 23 | 100 | 0 | 0 | |
| Beijing | 1 | 1 | 0.13 | 1 | 100 | 0 | 0 | |
| CAS1_DELHI | 26 | 1 | 0.13 | 0 | 0 | 1 | 100 | |
| H | 62 | 68 | 9.18 | 34 | 50 | 34 | 50 | |
| H | 50 | 33 | 4.45 | 18 | 54.55 | 14 | 42.42 | 1 |
| H | OTHERS | 28 | 3.78 | 19 | 67.86 | 9 | 32.14 | |
| H | 727 | 14 | 1.89 | 5 | 35.71 | 9 | 64.29 | |
| Orphan | NR | 126 | 17 | 91 | 72.22 | 32 | 25.4 | 3 |
| LAM | 42 | 183 | 24.7 | 116 | 63.39 | 63 | 34.43 | 4 |
| LAM | OTHERS | 45 | 6.07 | 27 | 60 | 15 | 33.33 | 3 |
| LAM | 33 | 18 | 2.43 | 11 | 61.11 | 7 | 38.89 | |
| LAM | 20 | 15 | 2.02 | 11 | 73.33 | 4 | 26.67 | |
| LAM | 17 | 19 | 2.56 | 16 | 84.21 | 3 | 15.79 | |
| LAM | 130 | 11 | 1.48 | 9 | 81.82 | 2 | 18.18 | |
| LAM | 162 | 9 | 1.21 | 7 | 77.78 | 2 | 22.22 | |
| M bovis | 820 | 1 | 0.13 | 0 | 0 | 1 | 100 | |
| MANU S | 54 | 4 | 0.54 | 0 | 0 | 0 | 0 | 4 |
| S | 34 | 7 | 0.94 | 4 | 57.14 | 3 | 42.86 | |
| S | 831 | 1 | 0.13 | 1 | 100 | 0 | 0 | |
| T | 53 | 51 | 6.88 | 17 | 33.33 | 23 | 45.1 | 11 |
| T | OTHERS | 23 | 3.1 | 10 | 43.48 | 13 | 56.52 | |
| U | 881 | 20 | 2.7 | 14 | 70 | 6 | 30 | |
| U | OTHERS | 10 | 1.35 | 9 | 90 | 1 | 10 | |
| U | 106 | 8 | 1.08 | 7 | 87.5 | 1 | 12.5 | |
| U | 523 | 9 | 1.21 | 0 | 0 | 0 | 0 | 9 |
| X | 91 | 5 | 0.67 | 2 | 40 | 3 | 60 | |
| X | OTHERS | 8 | 1.08 | 7 | 87.5 | 1 | 12.5 | |
| TOTAL | 741 | 100 | 460 | 62.08 | 246 | 33.2 | 35 | |
Fig 1Major genotypes identified according to family and frequency in Colombia, 1999–2012.
Bivariate analysis of the variables associated with grouping isolates.
| Variables | Grouping | p | ||||
|---|---|---|---|---|---|---|
| Yes | No | |||||
| n | % | n | % | |||
| Sex | ||||||
| Male | 357 | 79.3 | 93 | 20.6 | ||
| Female | 234 | 80.4 | 57 | 19.6 | 0.397 | |
| Age | ||||||
| 0–15 years | 10 | 90.9 | 1 | 9.1 | 0.21 | |
| 16–30 years | 215 | 83 | 44 | 71 | 0.137 | |
| 31–45 years | 167 | 76.6 | 51 | 23.4 | 0.385 | |
| 46–60 years | 118 | 80.3 | 29 | 19.7 | 0.243 | |
| 61–75 years | 28 | 65.1 | 15 | 34.9 | 0.379 | |
| >76 years | 18 | 72 | 7 | 28 | ref | |
| Status of treatment | ||||||
| PT | 132 | 81.9 | 29 | 18.1 | ||
| NT | 459 | 79.1 | 121 | 20.8 | 0.24 | |
| Susceptibility to first-line drugs | ||||||
| R | 369 | 80.4 | 90 | 19.6 | ||
| S | 192 | 77.7 | 55 | 22.3 | ||
| ND | 30 | 85.7 | 5 | 14.3 | 0.229 | |
| MDR | ||||||
| Yes | 125 | 85 | 22 | 14.9 | ||
| No | 466 | 78.4 | 128 | 21.5 | 0.045 | |
| Period of the study | ||||||
| 1999–2005 | 323 | 78.8 | 87 | 21.2 | ||
| 2006–2012 | 268 | 77.7 | 63 | 19 | 0.26 | |
| Family | ||||||
| LAM | 280 | 93.3 | 20 | 6.7 | ref | |
| Beijing | 23 | 95.8 | 1 | 4.8 | 0.527 | |
| U | 45 | 95.7 | 2 | 4.3 | 0.51 | |
| S | 7 | 87.5 | 1 | 12.5 | 0.435 | |
| H | 125 | 87.4 | 18 | 12.6 | 0.031 | |
| X | 8 | 61.5 | 5 | 38.5 | 0.001 | |
| T | 54 | 72.9 | 20 | 27.1 | <0.001 | |
| Orphan | 45 | 35.7 | 81 | 64.3 | <0.001 | |
| MANU | 4 | 100 | 0 | 0 | NA | |
| M. bovis | 0 | 0 | 1 | 100 | NA | |
| CAS1_Delhi | 0 | 0 | 1 | 100 | NA | |
* Test of significance: Fisher’s Exact
Bivariate analysis of the variables associated with drug resistance.
| Variables | Drug resistance | p | ||||
|---|---|---|---|---|---|---|
| Yes | No | |||||
| n | % | n | % | |||
| Sex | ||||||
| Male | 276 | 65.7 | 144 | 34.3 | ||
| Female | 182 | 63.9 | 103 | 36.1 | 0.334 | |
| Age | ||||||
| 0–15 years | 8 | 72.7 | 3 | 27.3 | 0.285 | |
| 16–30 years | 156 | 61.7 | 97 | 38.3 | 0.363 | |
| 31–45 years | 141 | 66.2 | 72 | 33.8 | 0.212 | |
| 46–60 years | 95 | 66 | 49 | 34 | 0.229 | |
| 61–75 years | 32 | 74.4 | 11 | 25.6 | 0.098 | |
| >76 years | 14 | 56 | 11 | 44 | ref | |
| Status of treatment | ||||||
| PT | 146 | 90.7 | 15 | 9.3 | ||
| NT | 313 | 57.4 | 232 | 42.6 | <0.001 | |
| Grouping | ||||||
| Yes | 369 | 65.8 | 192 | 34.2 | ||
| No | 90 | 62.1 | 55 | 37.9 | 0.229 | |
| Period of the study | ||||||
| 1999–2005 | 326 | 79.9 | 82 | 20.1 | ||
| 2006–2012 | 133 | 44.6 | 165 | 55.4 | <0.001 | |
| Family | ||||||
| LAM | 197 | 67.2 | 96 | 32.8 | ref | |
| Beijing | 9 | 69.2 | 4 | 30.8 | 0.527 | |
| U | 5 | 62.5 | 3 | 37.5 | 0.522 | |
| S | 91 | 73.9 | 32 | 26.1 | 0.105 | |
| H | 30 | 78.9 | 8 | 21.1 | 0.098 | |
| X | 76 | 53.5 | 66 | 46.5 | 0.003 | |
| T | 27 | 42.9 | 36 | 57.1 | <0.001 | |
| Orphan | 24 | 100 | 0 | 0 | ||
| MANU | 0 | 100 | 1 | 0 | NA | |
| M. bovis | 0 | 0 | 1 | 100 | NA | |
| CAS1_Delhi | 0 | 0 | 1 | 100 | NA | |
* Test of significance: Fisher’s Exact
Fig 2Distribution of the genotypic families according to the isolation period.
Fig 3Transmission dynamics of genotypes in isolates resistant (A) and sensitive (B) to first-line drugs.